These results indicate that bortezomib specifically benefits non-GCB DLBCL patients, who normally exhibit inferior outcomes relative to GCB subtype patients after therapy with CHOP or R-CHOP. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.